Amgen submitted a supplemental Biologics Licence Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of Xgeva…
News
Kite Pharma’s genetically modified T-cell therapy KITE-585 has delayed tumor progression and increased survival in mice with multiple myeloma, according to a preclinical-trial study. The…
Treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD), in addition to a stem cell transplant, improved progression-free survival among multiple myeloma patients…
Poseida Therapeutics‘ P-BCMA-101 eradicates tumors in mouse models of multiple myeloma and creates memory T-cells that go on the attack when the disease returns, preclinical…
The patient-led Global Myeloma Action Network (GMAN) recently designated March 30 as International Myeloma Action Day to raise awareness of multiple myeloma, advocate for early detection and…
The Leukemia & Lymphoma Society (LLS) and the National Black Church Initiative (NBCI) are closing March, Myeloma Awareness Month, with the start of…
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
